List view / Grid view
23 April 2015 | By Victoria White
The MHRA has granted a PIM designation for Novartis’ investigational medicine for patients with heart failure with reduced ejection fraction, LCZ696...
23 April 2015 | By Victoria White
Mobidiag, a molecular diagnostics company, will present two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015...
23 April 2015 | By Victoria White
Now that ellaOne is available in UK Pharmacy without prescription, HRA Pharma UK is launching a training programme to support its introduction...
22 April 2015 | By Victoria White
Bionomics has initiated a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression...
22 April 2015 | By Victoria White
Orexo has announced data from a trial assessing the long-term safety and efficacy of Zubsolv sublingual tablet for the treatment of opioid dependence...
22 April 2015 | By Victoria White
Cortice Biosciences has announced interim results a Phase 1/2 trial evaluating TPI 287 plus bevacizumab for the treatment of glioblastoma multiforme...
22 April 2015 | By Victoria White
Merck has reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases...
22 April 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the publication of results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit...
22 April 2015 | By Victoria White
Nimbus Therapeutics has initiated a Phase I clinical programme for NDI-010976 for the treatment of NASH and related fatty liver disease-spectrum disorders...
22 April 2015 | By Victoria White
Pfizer’s XALKORI has received Breakthrough Therapy designation from the FDA for the potential treatment of patients with ROS1-positive NSCLC...
22 April 2015 | By Victoria White
Teva has announced their proposal to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share...
22 April 2015 | By Victoria White
GW Pharmaceuticals has initiated the second Phase 3 clinical trial of Epidiolex for the treatment of Dravet syndrome, a rare form of childhood epilepsy...
21 April 2015 | By Victoria White
Pfizer Phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)...
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...
21 April 2015 | By Cobalt Light Systems
Cobalt Light Systems has been named as a recipient of the prestigious 2015 Queen’s Award for Enterprise...
